The effects of nefazodone on sleep architecture in depression

R. Armitage, J. Rush, M. Trivedi, J. Cain, H. P. Roffwarg

Research output: Contribution to journalArticle

104 Citations (Scopus)

Abstract

A polysomnographic study was conducted on 10 outpatients with major depression at baseline and during 4 to 8 weeks of open-trial treatment with nefazodone (400 to 600 mg/day). All 10 patients were treatment responders as evidenced by at least 50% reduction from baseline scores on the Hamilton Depression Rating Scale. Nefazodone was associated with significantly decreased wake and movement time and increased minutes and percentage of stage 2 sleep at the expense of light stage 1 sleep. Nefazodone did not increase rapid-eye-movement (REM) latency and it did not suppress REM sleep. In fact, a trend toward increased REM in the second REM period was observed, although decreased REM in the third REM period was also noted. In summary, nefazodone, an effective antidepressant, decreases arousals and wakefulness during sleep and reduces light non-REM sleep. This agent does not appear to suppress REM sleep or prolong REM latency in patients who respond to treatment.

Original languageEnglish (US)
Pages (from-to)123-127
Number of pages5
JournalNeuropsychopharmacology
Volume10
Issue number2
StatePublished - 1994

Fingerprint

REM Sleep
Sleep
Depression
Sleep Stages
Light
nefazodone
Wakefulness
Eye Movements
Arousal
Antidepressive Agents
Outpatients
Therapeutics

Keywords

  • 5-HT
  • antidepressants
  • depression
  • electroencephalographic sleep
  • nefazodone

ASJC Scopus subject areas

  • Pharmacology

Cite this

The effects of nefazodone on sleep architecture in depression. / Armitage, R.; Rush, J.; Trivedi, M.; Cain, J.; Roffwarg, H. P.

In: Neuropsychopharmacology, Vol. 10, No. 2, 1994, p. 123-127.

Research output: Contribution to journalArticle

Armitage, R, Rush, J, Trivedi, M, Cain, J & Roffwarg, HP 1994, 'The effects of nefazodone on sleep architecture in depression', Neuropsychopharmacology, vol. 10, no. 2, pp. 123-127.
Armitage, R. ; Rush, J. ; Trivedi, M. ; Cain, J. ; Roffwarg, H. P. / The effects of nefazodone on sleep architecture in depression. In: Neuropsychopharmacology. 1994 ; Vol. 10, No. 2. pp. 123-127.
@article{bfc00bc3f8dd4d4fb6d59b0e5c4f04fe,
title = "The effects of nefazodone on sleep architecture in depression",
abstract = "A polysomnographic study was conducted on 10 outpatients with major depression at baseline and during 4 to 8 weeks of open-trial treatment with nefazodone (400 to 600 mg/day). All 10 patients were treatment responders as evidenced by at least 50{\%} reduction from baseline scores on the Hamilton Depression Rating Scale. Nefazodone was associated with significantly decreased wake and movement time and increased minutes and percentage of stage 2 sleep at the expense of light stage 1 sleep. Nefazodone did not increase rapid-eye-movement (REM) latency and it did not suppress REM sleep. In fact, a trend toward increased REM in the second REM period was observed, although decreased REM in the third REM period was also noted. In summary, nefazodone, an effective antidepressant, decreases arousals and wakefulness during sleep and reduces light non-REM sleep. This agent does not appear to suppress REM sleep or prolong REM latency in patients who respond to treatment.",
keywords = "5-HT, antidepressants, depression, electroencephalographic sleep, nefazodone",
author = "R. Armitage and J. Rush and M. Trivedi and J. Cain and Roffwarg, {H. P.}",
year = "1994",
language = "English (US)",
volume = "10",
pages = "123--127",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - The effects of nefazodone on sleep architecture in depression

AU - Armitage, R.

AU - Rush, J.

AU - Trivedi, M.

AU - Cain, J.

AU - Roffwarg, H. P.

PY - 1994

Y1 - 1994

N2 - A polysomnographic study was conducted on 10 outpatients with major depression at baseline and during 4 to 8 weeks of open-trial treatment with nefazodone (400 to 600 mg/day). All 10 patients were treatment responders as evidenced by at least 50% reduction from baseline scores on the Hamilton Depression Rating Scale. Nefazodone was associated with significantly decreased wake and movement time and increased minutes and percentage of stage 2 sleep at the expense of light stage 1 sleep. Nefazodone did not increase rapid-eye-movement (REM) latency and it did not suppress REM sleep. In fact, a trend toward increased REM in the second REM period was observed, although decreased REM in the third REM period was also noted. In summary, nefazodone, an effective antidepressant, decreases arousals and wakefulness during sleep and reduces light non-REM sleep. This agent does not appear to suppress REM sleep or prolong REM latency in patients who respond to treatment.

AB - A polysomnographic study was conducted on 10 outpatients with major depression at baseline and during 4 to 8 weeks of open-trial treatment with nefazodone (400 to 600 mg/day). All 10 patients were treatment responders as evidenced by at least 50% reduction from baseline scores on the Hamilton Depression Rating Scale. Nefazodone was associated with significantly decreased wake and movement time and increased minutes and percentage of stage 2 sleep at the expense of light stage 1 sleep. Nefazodone did not increase rapid-eye-movement (REM) latency and it did not suppress REM sleep. In fact, a trend toward increased REM in the second REM period was observed, although decreased REM in the third REM period was also noted. In summary, nefazodone, an effective antidepressant, decreases arousals and wakefulness during sleep and reduces light non-REM sleep. This agent does not appear to suppress REM sleep or prolong REM latency in patients who respond to treatment.

KW - 5-HT

KW - antidepressants

KW - depression

KW - electroencephalographic sleep

KW - nefazodone

UR - http://www.scopus.com/inward/record.url?scp=0028337144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028337144&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 123

EP - 127

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 2

ER -